Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 7/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MAOA | P21397 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA3 | P07451 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | CA6 | P23280 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3371655 | 0.88 | ALOX5 (0.61) | ALOX5CYP3A4MAOBNPC1MEN1 | |
| SCHEMBL23412853 | 0.83 | KDM4E (0.49) | ALOX5NPC1RAB9AHRH3MAPT | |
| SCHEMBL28191785 | 0.80 | AGXT (0.36) | ALOX5MAOBNPC1RAB9AMAPT | |
| SCHEMBL28020295 | 0.80 | NPC1 (0.37) | ALOX5MAOBNPC1MEN1KMT2A | |
| SCHEMBL51460 | 0.77 | ALOX5 (1.00) | ALOX5CYP3A4MAOBNPC1MEN1 | |
| SCHEMBL28662350 | 0.76 | ALOX5 (0.89) | ALOX5CYP3A4MAOBNPC1MEN1 | |
| SCHEMBL23412203 | 0.75 | KDM4E (0.57) | NPC1RAB9AHRH3MAPTSMN1; SMN2 | |
| SCHEMBL6999744 | 0.75 | ALOX5 (0.68) | ALOX5CYP3A4MAOBNPC1MEN1 | |
| SCHEMBL8984340 | 0.73 | ALOX5 (0.92) | ALOX5CYP3A4MAOBNPC1MEN1 | |
| Methyl Alcohol SCHEMBL29235268 | 0.73 | ALOX5 (0.89) | ALOX5CYP3A4MAOBNPC1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021105497-A1 | SMALL-MOLECULE NADPH OXIDASE 2 INHIBITORS | UNIVERSITY OF COPENHAGEN (DK) | 2021-06-03 | — | — | WO | disclosed |
| EP-2270006-A1 | Pyridazine derivatives useful as vanilloid receptor ligands | Amgen, Inc (US) | 2011-01-05 | — | — | EP | disclosed |
| US-7332511-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-7332511-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-7148221-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2006-12-12 | — | — | US | disclosed |
| US-7144888-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2006-12-05 | — | — | US | disclosed |
| EP-1717220-A2 | Vanilloid receptor ligands and their use in treatments | Amgen, Inc (US) | 2006-11-02 | — | — | EP | disclosed |
| EP-1688408-A2 | Vanilloid receptor ligands and their use in treatments | Amgen, Inc (US) | 2006-08-09 | — | — | EP | disclosed |
| US-20050277631-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2005-12-15 | — | — | US | disclosed |
| US-20050272777-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2005-12-08 | — | — | US | disclosed |
| CN-1694873-A | Vanilloid receptor ligands and their use in treatments | AMGEN INC (US) | 2005-11-09 | — | — | CN | disclosed |
| EP-1546116-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | Amgen Inc. (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20040082780-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN, INC. | 2004-04-29 | — | — | US | disclosed |
| WO-2004014871-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272777-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | ALOX5 839/4885CYP3A4 1962/4885MAOB 1213/4885 |
| US-20050277631-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | ALOX5 839/4885CYP3A4 1962/4885MAOB 1213/4885 |
| US-20040082780-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | ALOX5 854/4885CYP3A4 2078/4885MAOB 1137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.